On January 9, 2024, the PTAB issued final written decisions in
IPR2022-01225 and IPR2022-01226, filed by Mylan on two Regeneron
patents directed to dosing of aflibercept — U.S. Patent Nos.
10,130,681 and 10,888,601. The PTAB ruled that all challenged
claims of the '681 patent (claims 1, 3-11, 13, 14, 16-24, and
26) and the '601 patent (claims 1-9, 34-39. 41-43, and 45) are
invalid as anticipated by the same prior art reference.
As we previously reported, Celltrion and Samsung also filed IPR
petitions challenging claims of the '681 and '601 patents.
Celltrion's IPR2023-00532, challenging claims of '681
patent, had been joined with Mylan's IPR2022-01255.
Celltrion's IPR2023-00533 and Samsung's IPR2023-0566, both
challenging claims of the '601 patent, had been joined with
Mylan's IPR2022-01226. Samsung's IPR2023-00442, challenging
claims of the '681 patent, remains pending before the PTAB.